Prevalent and persistent oncogenic HPV types in a cohort of women living with HIV prior to HPV vaccination.
Adult
Female
HIV Infections
/ complications
Humans
Middle Aged
Papillomavirus Infections
/ classification
Papillomavirus Vaccines
/ immunology
Prospective Studies
Uterine Cervical Neoplasms
/ prevention & control
Vaccination
/ statistics & numerical data
Uterine Cervical Dysplasia
/ prevention & control
Canada
Cervical cancer
Cervical cytology
Cervix screening
HIV
HPV
Women
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
29
10
2019
revised:
11
03
2020
accepted:
23
04
2020
pubmed:
29
4
2020
medline:
30
9
2020
entrez:
29
4
2020
Statut:
ppublish
Résumé
To describe prevalent and persistent oncogenic human papillomavirus (HPV) types detected in women living with HIV (WLWH) in Canada, including women with cervical dyskaryosis, and to determine predictors of type-specific HPV persistence. Women and girls living with HIV, recruited from 14 sites of HIV care across Canada, were included in a sub-analysis of a prospective vaccine immunogenicity cohort study (two HPV DNA results, at least one cervical cytology result pre-vaccination). Demographic and clinical data were collected alongside cervical samples for cytology and HPV DNA typing between November 25, 2008, and May 19, 2015. Pre-vaccination, HPV16 and HPV52 were the most prevalent oncogenic HPV types. Of the 252 women and girls who met the eligibility criteria, 45% were infected with at least one oncogenic HPV type and one-third of participants had a persistent oncogenic infection. HPV16, 45, and 52 were the most frequently persistent types. Seventeen percent of women had persistent infections with oncogenic HPV types not within currently available vaccines (HPV35/39/51/56/59/68/82). Lower CD4 count significantly predicted HPV persistence (P=0.024). Cervical cytology results were normal for 82.9% of participants, atypical squamous cells of undetermined significance for 2.4%, low-grade squamous intraepithelial lesions for 11.5%, and high-grade squamous intraepithelial lesions for 2.8%. Unvaccinated WLWH were infected with a wide range of oncogenic HPV types. The findings highlighted the importance of optimal treatment of HIV and continued cervical cancer screening as key steps toward the global elimination of cervical cancer.
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108-115Subventions
Organisme : Canadian Institutes of Health Research (CIHR)
Organisme : CIHR Canadian HIV Trials Network
Organisme : Merck Canada Inc
Informations de copyright
© 2020 International Federation of Gynecology and Obstetrics.
Références
Small W, Bacon MA, Bajaj A, et al. Cervical cancer: A global health crisis. Cancer. 2017;123:2404-2412.
Gallagher KE, LaMontagne DS, Watson-Jones D. Status of HPV vaccine introduction and barriers to country uptake. Vaccine. 2018;36:4761-4767.
Blitz S, Baxter J, Raboud J, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. Journal Infect Dis. 2013;208:454.
Massad LS, Xie X, Burk R, et al. Long-term cumulative detection of human papillomavirus among HIV seropositive women. AIDS. 2014;28:2601-2608.
Massad LS, Riester KA, Anastos KM, Fruchter RG. Prevalence and predictors of squamous cell abnormalities in papanicolaou smears from women infected with HIV-1. J Acquir Immune Deficiency Syndr. 1999;21:33-41.
Strickler HD, Burk RD, Fazzari M, et al. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J Natl Cancer Inst. 2005;97:577-586.
Abraham AG, D'Souza G, Jing YZ, et al. Invasive cervical cancer risk among HIV-infected women: A North American Multicohort Collaboration Prospective Study. J Acquir Immune Deficiency Syndr. 2013;62:405-413.
Joura EA, Kjaer SK, Wheeler CM, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008;26:6844-6851.
Muñoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373:1949-1957.
Villa LL, Perez G, Kjaer SK, et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Engl J Med. 2007;356:1915-1927.
McClymont E, Lee M, Raboud J, et al. The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with HIV. Clin Infect Dis. 2019;68:788-794.
Wilkin TJ, Chen H, Cespedes MS, et al. A randomized, placebo-controlled trial of the quadrivalent HPV vaccine in HIV-infected adults age 27 years or older: AIDS Clinical Trials Group protocol A5298. Clin Infect Dis. 2018;67:1339-1346.
Hankins C, Coutlee F, Lapointe N, et al. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Can Med Assoc J. 1999;160:185-191.
Clifford GM, Goncalves MAG, Franceschi S, HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006;20:2337-2344.
Money DM, Moses E, Blitz S, et al. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine. 2016;34:4799-4806.
Coutlée F, Rouleau D, Petignat P, et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the linear array HPV genotyping test. J Clin Microbiol. 2006;44:1998-2006.
Tornesello ML, Buonaguro FM, Bethgiraldo E, Giraldo G. Human-immunodeficiency-virus type-1 tat gene enhances human papillomavirus early gene-expression. Intervirology. 1993;36:57-64.
Tugizov SM, Herrera R, Chin-Hong P, et al. HIV-associated disruption of mucosal epithelium facilitates paracellular penetration by human papillomavirus. Virology. 2013;446:378-388.
Massad LS, Xie X, Burk RD, et al. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women. Am J Obstet Gynecol. 2016;214:354.e1-354.e6.
Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis. Am J Epidemiol. 2008;168:123-137.